Lake C R, Wood J H, Ziegler M G, Ebert M H, Kopin I J
Arch Gen Psychiatry. 1978 Feb;35(2):237-40. doi: 10.1001/archpsyc.1978.01770260115014.
Probenecid administered in divided oral doses totaling 100 mg/kg increased levels of norepinephrine (NE) in plasma and cerebrospinal fluid (CSF). This technique is commonly used to measure the rate of accumulation of acidic metabolites of certain brain neurotransmitter biogenic amines in CSF after blockade of their transport into blood. Since levels of 3-methoxy-4-hydroxy-phenylethyleneglycol, a neutral metabolite of NE, are also elevated after high oral doses of probenecid, the increases of CSF and plasma NE levels may be directly related to probenecid-induced release of this amine from noradrenergic neurons. In patients who experienced nausea or vomiting there were lower levels of probenecid in CSF, probably secondary to diminished absorption of the medication. These patients also had lower levels of NE in plasma than did patients who remained asymptomatic.
口服丙磺舒，总剂量达100mg/kg，分多次服用，可使血浆和脑脊液（CSF）中的去甲肾上腺素（NE）水平升高。该技术通常用于在某些脑内神经递质生物胺的酸性代谢产物向血液转运受阻后，测量其在脑脊液中的蓄积速率。由于口服大剂量丙磺舒后，NE的中性代谢产物3-甲氧基-4-羟基苯乙二醇的水平也会升高，因此脑脊液和血浆NE水平的升高可能与丙磺舒诱导去甲肾上腺素能神经元释放这种胺直接相关。出现恶心或呕吐的患者脑脊液中丙磺舒水平较低，这可能是由于药物吸收减少所致。这些患者血浆中的NE水平也低于无症状患者。
